Immunowake is a biotechnology company that focuses on identifying new therapies for patients who do not respond to existing immunotherapies.
Immunowake has raised $20.0M in total funding. The most recent round was Series A. The last funding was announced in May 2022.
Immunowake's investors include Lapam Capital, South China Venture Capital, HEDA Ventures, Hyfinity Investments.
Immunowake is headquartered in Birmingham, United States.
Immunowake is a biotechnology company that focuses on identifying new therapies for patients who do not respond to existing immunotherapies.
Immunowake is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Immunowake — Funding & Investors." VCBacked, May 15, 2022, https://www.vcbacked.co/company/immunowake. Accessed August 16, 2026.
VCBacked. (2022). Immunowake — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/immunowake
{{cite web |title=Immunowake — Funding & Investors |url=https://www.vcbacked.co/company/immunowake |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated